|
||||||
|
 | |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
|
Gene: ENSG00000132326 |
Summary for PER2 |
 Gene summary |
| Gene information | Ensembl ID | ENSG00000132326 | Gene symbol | PER2 |
| Gene name | period circadian regulator 2 | |
| HGNC | 8846 | |
| Entrez ID | 8864 | |
| Gene type | protein_coding | |
| Synonyms | PER2|KIAA0347 | |
| UniProtAcc | O15055 |
| Drugs associated with this gene(DrugBank). |
| Gene ID | Gene Symbol | Drug ID | Drug Name | Drug Type |
| Cancer therapeutic drugs associated with this gene(NCI). |
| Gene ID | Gene Name | Drug ID | Drug Name | Drug Type | Cancer |
Top |
Structure and expression level for PER2 |
| AS events and RNA A-to-I editing events of the gene in TCGA based on Genvode V22 structure. ∗For more information on exon skipping events please check the ExonskipDB database. ∗For more information on exon skipping events please check the CAeditome database. |
 |
| Landscape of gene expressions across multiple cancer types. |
 |
| Differentially expressed gene analysis between tumor male and tumor female samples. |
| Coding Name | Base Mean | log2FoldChange | lfcSE | Stat | P value | P.adjust Value | Cancer Type |
| Differentially expressed gene analysis between tumor male and normal male samples. |
 |
| Coding Name | Base Mean | log2FoldChange | lfcSE | Stat | P value | P.adjust Value | Cancer Type |
| PER2 | 8.83e+02 | -1.15e+00 | 2.39e-01 | -4.80e+00 | 1.55e-06 | 7.58e-06 | KICH |
| Differentially expressed gene analysis between tumor female and normal female samples. |
 |
| Coding Name | Base Mean | log2FoldChange | lfcSE | Stat | P value | P.adjust Value | Cancer Type |
| PER2 | 2.51e+03 | -1.25e+00 | 6.88e-02 | -1.81e+01 | 3.76e-73 | 7.35e-72 | BRCA |
Top |
Sex-biased somatic mutation for PER2 |
| ∗For more information on exon skipping events please check the ExonskipDB database. |
| Gene ID | Cancer Type | Hugo Symbol | Male | Female | pval | or | ci.up | ci.low | adjPval |
Top |
DNA methylation with beta values for PER2 |
| Landscape of DNA methylation across multiple cancer types. |
 |
| Differentially expressed CpG sites between male tumor and female tumor patients. |
| Cancer Type | CpG Site | Position | CpG Island | Position to Gene | ave1 | ave2 | wilcoxon.w | wilcoxon.p | padj | dBeta |
| Differentially expressed CpG sites between male tumor and male normal patients. |
| Cancer Type | CpG Site | Position | CpG Island | Position to Gene | ave1 | ave2 | wilcoxon.w | wilcoxon.p | padj | dBeta |
| LUSC | cg04169774 | chr2:238289796 | CGI:chr2:238288282-238289186 | promoter,gene body | 3.97e-01 | 5.06e-01 | -2.77e+00 | 5.53e-03 | 8.80e-03 | -1.09e-01 |
| CHOL | cg05664072 | chr2:238289653 | CGI:chr2:238288282-238289186 | promoter,gene body | 2.03e-01 | 5.15e-01 | -2.95e+00 | 3.19e-03 | 1.32e-02 | -3.12e-01 |
| CHOL | cg04169774 | chr2:238289796 | CGI:chr2:238288282-238289186 | promoter,gene body | 5.76e-01 | 7.09e-01 | -2.14e+00 | 3.25e-02 | 3.87e-02 | -1.32e-01 |
| CHOL | cg10780517 | chr2:238290177 | CGI:chr2:238288282-238289186 | promoter | 2.41e-01 | 3.43e-01 | -2.14e+00 | 3.25e-02 | 3.87e-02 | -1.02e-01 |
| Differentially expressed CpG sites between female tumor and female normal patients. |
| Cancer Type | CpG Site | Position | CpG Island | Position to Gene | ave1 | ave2 | wilcoxon.w | wilcoxon.p | padj | dBeta |
| BRCA | cg12912690 | chr2:238288816 | CGI:chr2:238288282-238289186 | promoter,gene body | 2.75e-01 | 1.32e-01 | 1.18e+01 | 3.70e-32 | 7.10e-31 | 1.43e-01 |
| HNSC | cg04169774 | chr2:238289796 | CGI:chr2:238288282-238289186 | promoter,gene body | 4.59e-01 | 3.22e-01 | 2.52e+00 | 1.17e-02 | 2.02e-02 | 1.36e-01 |
Top |
Exon skipping events with PSI in TCGA for PER2 |
| ∗Please access ExonSkipDB for exon skipping annotation. |
| Landscape of exon skipping events across multiple cancer types. |
 |
| Differentially expressed exon skipping events between male tumor and female tumor patients. |
| Cancer Type | Exon Skipping | ave.female_T | ave.female_N | wilcoxon.w | wilcoxon.p | padj | dPSI |
| Differentially expressed exon skipping events between male tumor and male normal patients. |
| Cancer Type | Exon Skipping | ave.female_T | ave.female_N | wilcoxon.w | wilcoxon.p | padj | dPSI |
| Differentially expressed exon skipping events between female tumor and female normal patients. |
| Cancer Type | Exon Skipping | ave.female_T | ave.female_N | wilcoxon.w | wilcoxon.p | padj | dPSI |
Top |
RNA A-to-I editing events in TCGA for PER2 |
| ∗Please access CAeditome for RNA editing annotation. |
| Differentially expressed RNA editing events between male tumor and female tumor patients. |
| Cancer Type | Transcript | Editing | ave.male_T | ave.female_T | wilcoxon.w | wilcoxon.p | p_adj | dFre |
| Differentially expressed RNA editing events between male tumor and male normal patients. |
| Cancer Type | Transcript | Editing | ave.male_T | ave.female_T | wilcoxon.w | wilcoxon.p | p_adj | dFre |
| Differentially expressed RNA editing events between female tumor and female normal patients. |
| Cancer Type | Transcript | Editing | ave.male_T | ave.female_T | wilcoxon.w | wilcoxon.p | p_adj | dFre |
| Protein coding RNA editing(s). |
| Editing Position | Variant Type | Gene Symbol | Transcript ID | NTchange | AAchange |
Top |
Sex-biased TF-Gene network for PER2 |
| TFs related to PER2. ∗The female-biased TF-gene edges were identified if Female_Edge_threshold>0.98 and Male_Edge_threshold<=0.98. ∗The male-biased TF-gene edges were identified if Male_Edge_threshold>0.98 and Female_Edge_threshold<=0.98. |
 |
| Cancer Type | TF | Target Gene | Male Edge Score | Male Edge Threshold | Female Edge Score | Female Edge Threshold | Type |
| DLBC | PRDM6 | PER2 | 4.48e+00 | 9.85e-01 | 3.57e+00 | 8.26e-03 | Male-biased |
| DLBC | ZNF235 | PER2 | 4.86e+00 | 9.89e-01 | 3.90e+00 | 6.76e-03 | Male-biased |
| DLBC | ZNF287 | PER2 | 4.78e+00 | 9.86e-01 | 3.91e+00 | 9.90e-03 | Male-biased |
| PER2 related gene. ∗Only the gene encode TF might with this result. ∗For more information please check Sex-biased TF-Coding gene network. |
Top |
Sex-biased RBP-ES network for PER2 |
| RBPs related to ES in PER2. ∗The female-biased RBP-ES edges were identified if Female_Edge_threshold>0.98 and Male_Edge_threshold<=0.98. ∗The male-biased RBP-ES edges were identified if Male_Edge_threshold>0.98 and Female_Edge_threshold<=0.98. |
 |
| Cancer Type | RBP | Target ES | Male Edge Score | Male Edge Threshold | Female Edge Score | Female Edge Threshold | Type |
| STAD | SAMD4A | exon_skip_347643 | 7.03e+00 | 9.86e-01 | 6.32e+00 | 6.85e-04 | Male-biased |
| PER2 related ES. ∗Only the gene encode RBP might with this result. ∗For more information please check Sex-biased RBP-ES network in cancer. |
Top |
Sex-biased CeRNA regulation of gene |
| Sex-biased CeRNA regulation of gene. |
| Gene ID | ceRNA(lncRNA-miRNA-mRNA) | Group | Cancer Type |
Top |
Sex-biased eQTL regulation of gene |
| Sex-biased eQTL regulation of gene (The figures only show the pairs with FDR <1e-5. For more information please check the below table). |
| eQTL | Description |
| Male-specific eQTL regulation. |
| SNP ID | SNP Info | Position to Gene | Effect Score | FDR | Cancer Type | Biased Type |
| rs747882 | chr2:230942466:G:A | - | 0.0551833428536401 | 0.00378509815225027 | THCA | Female-baised eQTL |
| Female-specific eQTL regulation. |
| SNP ID | SNP Info | Position to Gene | Effect Score | FDR | Cancer Type | Biased Type |
| rs12623067 | chr2:238645780:C:A | - | 0.109547657638292 | 0.0275754934517568 | SARC | Male-baised eQTL |
| rs34247524 | chr2:241136873:G:A | - | 0.130231250861101 | 0.00513092406622971 | LUAD | Male-baised eQTL |
| rs36072903 | chr2:241137552:G:A | - | 0.130231250861101 | 0.00513092406622971 | LUAD | Male-baised eQTL |
| rs10933530 | chr2:241137933:C:T | - | 0.130231250861101 | 0.00513092406622971 | LUAD | Male-baised eQTL |
| rs11682122 | chr2:241138919:T:C | - | 0.130231250861101 | 0.00513092406622971 | LUAD | Male-baised eQTL |
| rs6728712 | chr2:241139688:G:A | - | 0.130231250861101 | 0.00513092406622971 | LUAD | Male-baised eQTL |
| rs11686192 | chr2:241145940:C:A | - | 0.121892548358089 | 0.0068913764693716 | LUAD | Male-baised eQTL |
| rs35201353 | chr2:241173744:C:T | - | 0.124818211354653 | 0.00714328964513418 | LUAD | Male-baised eQTL |
| rs13035056 | chr2:241174822:C:A | - | 0.134404239902675 | 0.00722329578483715 | LUAD | Male-baised eQTL |
| rs114928224 | chr2:238744958:C:A | - | 0.125338776362391 | 0.0088422343368344 | LUAD | Male-baised eQTL |
| rs758072 | chr2:241144457:G:T | - | 0.117650923070454 | 0.0093655330670428 | LUAD | Male-baised eQTL |
| rs10933532 | chr2:241140138:C:T | - | 0.11728757739101 | 0.00975415482134417 | LUAD | Male-baised eQTL |
| rs11681962 | chr2:241138642:T:C | - | 0.12379119410568 | 0.0118231836106361 | LUAD | Male-baised eQTL |
| rs114467012 | chr2:234505615:T:C | - | 0.120814885696976 | 0.0207819309052634 | LUAD | Male-baised eQTL |
| rs75039188 | chr2:238743078:G:A | - | 0.10830650071753 | 0.0234054901258807 | LUAD | Male-baised eQTL |
| rs116525028 | chr2:234494244:A:G | - | 0.118799158652989 | 0.0257102008232925 | LUAD | Male-baised eQTL |
| rs113530329 | chr2:234495224:A:C | - | 0.118799158652989 | 0.0257102008232925 | LUAD | Male-baised eQTL |
| rs1981616 | chr2:241147445:C:T | - | 0.106992377794283 | 0.0268683039461097 | LUAD | Male-baised eQTL |
| rs78105388 | chr2:238749813:C:T | - | 0.10722504964034 | 0.0292561046256617 | LUAD | Male-baised eQTL |
| rs7423661 | chr2:234500535:T:G | - | 0.115572013558969 | 0.0316249911928121 | LUAD | Male-baised eQTL |
| rs76384797 | chr2:234501048:A:G | - | 0.115572013558969 | 0.0316249911928121 | LUAD | Male-baised eQTL |
| rs116060845 | chr2:234502065:C:A | - | 0.115572013558969 | 0.0316249911928121 | LUAD | Male-baised eQTL |
| rs72973059 | chr2:236067029:T:C | - | 0.124559620484254 | 0.0317902476599739 | LUAD | Male-baised eQTL |
| rs56722161 | chr2:236037299:C:T | - | 0.0734032334435193 | 0.0352940502709728 | LUAD | Male-baised eQTL |
| rs1551252 | chr2:236038634:A:G | - | 0.0734032334435193 | 0.0352940502709728 | LUAD | Male-baised eQTL |
| rs71430311 | chr2:241161959:C:T | - | 0.123910959803214 | 0.0355899375802574 | LUAD | Male-baised eQTL |
| rs6431420 | chr2:236039523:C:T | - | 0.0733753852476774 | 0.0370060971826836 | LUAD | Male-baised eQTL |
| rs11696044 | chr2:241137906:C:A | - | 0.121900020635684 | 0.0423471559652342 | LUAD | Male-baised eQTL |
| rs11676695 | chr2:241139846:C:G | - | 0.121900020635684 | 0.0423471559652342 | LUAD | Male-baised eQTL |
| rs11688480 | chr2:238742634:C:T | - | 0.105310518252718 | 0.0428540760723574 | LUAD | Male-baised eQTL |
| rs2123510 | chr2:236036076:C:G | - | 0.0715584227676619 | 0.0436627352097382 | LUAD | Male-baised eQTL |
| rs36112247 | chr2:241164679:G:A | - | 0.121482141036673 | 0.0441089877615267 | LUAD | Male-baised eQTL |
| rs73123785 | chr2:236032548:C:T | - | 0.0749704559749352 | 0.0455937655609583 | LUAD | Male-baised eQTL |
| rs1551251 | chr2:236039101:T:G | - | 0.0707248570909231 | 0.0466625275124989 | LUAD | Male-baised eQTL |
| rs11677056 | chr2:241152167:G:T | - | 0.120886148880676 | 0.0467550340075914 | LUAD | Male-baised eQTL |
| rs71430310 | chr2:241161489:C:T | - | 0.120886148880676 | 0.0467550340075914 | LUAD | Male-baised eQTL |
| rs169731 | chr2:239230401:T:C | - | -0.0473930775945918 | 0.0182978196799935 | COAD | Male-baised eQTL |
| rs12624045 | chr2:239701940:T:G | - | 0.0505384952047951 | 0.0233561755046856 | COAD | Male-baised eQTL |
| rs11693452 | chr2:239702605:C:T | - | 0.050550319016771 | 0.023547918850314 | COAD | Male-baised eQTL |
| Opposite sex-biased eQTL regulation. |
| SNP ID | SNP Info | Position to Gene | Male Effect | Male FDR | Female Effect | Female FDR | Sex-biased Gene in Cancer | Cancer Type |
Top |
Sex-biased eQTM regulation of gene |
| Sex-biased eQTM regulation of gene (The figures only show the pairs with FDR<1e-5. For more information please check the below table). |
| eQTM | Description |
 | Gene ID: ENSG00000132326 |
| CpG Site: cg24204951 | |
| Position to Gene: gene | |
| Male Effect: -0.379840199848066 | |
| Female Effect: - | |
 | Gene ID: ENSG00000132326 |
| CpG Site: cg11903188 | |
| Position to Gene: gene | |
| Male Effect: -0.39505375574186 | |
| Female Effect: - | |
 | Gene ID: ENSG00000132326 |
| CpG Site: cg23072629 | |
| Position to Gene: gene | |
| Male Effect: -0.071780083166529 | |
| Female Effect: - |
| Male-specific eQTM regulation. |
| CpG Site | CpG Postion | Position to Gene | Effect Score | FDR | Cor.r | Cor.Pvalue | Cancer Type |
| cg24204951 | chr2:238263443 | gene | -0.379840199848066 | 8.58353708190695e-14 | -0.5290255724001101 | 2.8954302266471654e-17 | LUAD |
| cg11903188 | chr2:238286961 | gene | -0.39505375574186 | 2.14219946026091e-06 | -0.32833618441177104 | 9.103268139953429e-09 | SKCM |
| cg23072629 | chr2:238286896 | gene | -0.071780083166529 | 7.59982058237904e-07 | -0.30120387946178573 | 4.108634433815357e-09 | HNSC |
| Female-specific eQTM regulation. |
| CpG Site | CpG Postion | Position to Gene | Effect Score | FDR | Cor.r | Cor.Pvalue | Cancer Type |
| Opposite sex-biased eQTM regulation. |
| CpG Site | CpG Postion | CpG Island | Position to Gene | Male Effect | Male FDR | Female Effect | Female FDR | Male Cor | Male P-value | Female Cor | Female P-value | Sex-biased Coding Gene | Cancer Type |
Top |
Sex-biased sQTL regulation of gene |
| Sex-biased sQTL regulation of gene (The figures only show the pairs with FDR <1e-5. For more information please check the below table). |
| sQTL | Description |
| Male-specific sQTL regulation. |
| ES ID | Skipped Exon | ORF Anno | SNP ID | SNP Info | SNP Position to ES | Effect Score | FDR | Cancer Type | Biased Type |
| Female-specific sQTL regulation. |
| ES ID | Skipped Exon | ORF Anno | SNP ID | SNP Info | SNP Position to ES | Effect Score | FDR | Cancer Type | Biased Type |
| Opposite sex-biased sQTL regulation. |
| ES ID | Skipped Exon | ORF Anno | SNP ID | SNP Info | SNP Position to ES | Male Effect | Male FDR | Female Effect | Female FDR | Cancer Type |
Top |
Sex-biased sQTM regulation of gene |
| Sex-biased sQTM regulation of gene (The figures only show the pairs with FDR <1e-5. For more information please check the below table). |
| sQTM | Description |
| Male-specific sQTM regulation. |
| EX ID | Skipped Exon | CPG Site | CPG Position | Position to EX Events | Effect Score | FDR | Cor.r | Cor.Pvalue | ORF_anno | Cancer Type |
| Female-specific sQTM regulation. |
| EX ID | Skipped Exon | CPG Site | CPG Position | Position to EX Events | Effect Score | FDR | Cor.r | Cor.Pvalue | ORF_anno | Cancer Type |
| Opposite sex-biased sQTM regulation. |
| EX ID | EX Info | Skipped Exon | CPG Site | CPG Position | CPG Island | Position to EX Events | Male Effect | Male FDR | Female Effect | Female FDR | Male Correlation | Male P-value | Female Correlation | Female P-value | ORF_anno | Cancer Type |
Top |
Related disease information of PER2 |
| Diseases associated with this gene (DisGeNET). |
| Gene ID | Gene Symbol | Disease ID | Disease Name | Number of PMID | Source |
| ENSG00000132326 | PER2 | C0001969 | Alcoholic Intoxication | 1 | CTD_human |
| ENSG00000132326 | PER2 | C0005586 | Bipolar Disorder | 4 | PSYGENET |
| ENSG00000132326 | PER2 | C0011570 | Mental Depression | 5 | PSYGENET |
| ENSG00000132326 | PER2 | C0011581 | Depressive disorder | 5 | PSYGENET |
| ENSG00000132326 | PER2 | C0023473 | Myeloid Leukemia, Chronic | 1 | CTD_human |
| ENSG00000132326 | PER2 | C0038587 | Substance Withdrawal Syndrome | 2 | CTD_human |
| ENSG00000132326 | PER2 | C0086189 | Drug Withdrawal Symptoms | 2 | CTD_human |
| ENSG00000132326 | PER2 | C0087169 | Withdrawal Symptoms | 2 | CTD_human |
| ENSG00000132326 | PER2 | C0221074 | Depression, Postpartum | 2 | PSYGENET |
| ENSG00000132326 | PER2 | C0600427 | Cocaine Dependence | 2 | PSYGENET |
| ENSG00000132326 | PER2 | C0858355 | Addicted to cocaine | 1 | PSYGENET |
| ENSG00000132326 | PER2 | C1858496 | Advanced Sleep-Phase Syndrome, Familial | 1 | CTD_human |
